Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer’s Disease

Barbara Rossi 1*, Bruno Santos-Lima 1, Eleonora Terrabuio 1, Elena Zenaro 1 and Gabriela Constantin 1,2*

1 Section of General Pathology, Department of Medicine, University of Verona, Verona, Italy, 2 The Center for Biomedical Computing (CBMC), University of Verona, Verona, Italy

Neurodegenerative diseases are closely related to inflammatory and autoimmune events, suggesting that the dysregulation of the immune system is a key pathological factor. Both multiple sclerosis (MS) and Alzheimer’s disease (AD) are characterized by infiltrating immune cells, activated microglia, astrocyte proliferation, and neuronal damage. Moreover, MS and AD share a common pro-inflammatory signature, characterized by peripheral leukocyte activation and transmigration to the central nervous system (CNS). MS and AD are both characterized by the accumulation of activated neutrophils in the blood, leading to progressive impairment of the blood–brain barrier. Having migrated to the CNS during the early phases of MS and AD, neutrophils promote local inflammation that contributes to pathogenesis and clinical progression. The role of circulating T cells in MS is well-established, whereas the contribution of adaptive immunity to AD pathogenesis and progression is a more recent discovery. Even so, blocking the transmigration of T cells to the CNS can benefit both MS and AD patients, suggesting that common adaptive immunity mechanisms play a detrimental role in each disease. There is also growing evidence that regulatory T cells are beneficial during the initial stages of MS and AD, supporting the link between the modulatory immune compartments and these neurodegenerative disorders. The number of resting regulatory T cells declines in both diseases, indicating a common pathogenic mechanism involving the dysregulation of these cells, although their precise role in the control of neuroinflammation remains unclear. The modulation of leukocyte functions can benefit MS patients, so more insight into the role of peripheral immune cells may reveal new targets for pharmacological intervention in other neuroinflammatory and neurodegenerative diseases, including AD.

Keywords: multiple sclerosis, Alzheimer’s disease, neuroinflammation, neutrophils, monocytes, T cells

INTRODUCTION

Multiple sclerosis (MS) and Alzheimer’s disease (AD) are two of the most widely studied central nervous system (CNS) pathologies. MS is the most common inflammatory neurological disease in young adults, whereas AD is a neurodegenerative disorder that occurs more frequently in the elderly population and is the most common type of dementia. The number of MS and AD patients is growing continuously, highlighting the need to find new disease mechanisms and new therapeutic
approaches (1, 2). MS and AD are both multifactorial diseases and the identification of their etiopathogenetic mechanisms is challenging. Genetic risk factors and environmental triggers are the principal risk factors for both MS and AD (3, 4).

From the neuropathological perspective, the early phases of MS, defined as relapsing–remitting MS (RRMS), are characterized by primary demyelination areas known as plaques, which are located in the white and gray matter. In contrast, the final phases (secondary progressive MS) are associated with axonopathy, neuronal death, and synaptic loss, correlating with the permanent motor disability classically shown by MS patients (5). AD neuropathology is characterized by two main hallmarks: amyloid β plaques and tau tangles. Both structures are formed from aggregated proteins, in one case due to the incorrect processing of amyloid precursor protein (APP), and in the other due to the hyperphosphorylation of tau, a microtubule-associated protein required to maintain neuronal architecture and function.

The involvement of immune and inflammatory reactions in the pathogenesis of MS has been understood for decades, but the same association was only recently identified in AD. The concept of CNS exclusion from surveillance and inflammatory responses mediated by peripheral immune cells was reconsidered more than 15 years ago describing how circulating immune cells enter into the brain for protective tissue immunosurveillance and has been recently reviewed following the discovery of the cerebral lymphatic system and its role in CNS physiology (6–8). Furthermore, strong evidence of peripheral immune cell trafficking into the CNS has been provided during the immune responses that occur during MS and its animal model, experimental autoimmune encephalomyelitis (EAE), confirming that the CNS is not an immune-privileged environment (9). More recently, immune cell trafficking has also been documented in AD and was shown to be detrimental in transgenic mice with AD-like disease (10, 11). Neuroinflammation in both MS and AD is also characterized by the activation of microglia and astrocytes, leading to the secretion of pro-inflammatory cytokines and chemokines that recruit more immune cells from the periphery to the CNS (12, 13). Interestingly, the specialized pro-resolving lipid mediators, which mediate inflammation resolution and reduce neutrophil and monocyte infiltration into the brain, are impaired in MS and AD patients and their levels correlate with disease severity (14–16). These defects in the resolution pathways further emphasize the common detrimental role of peripheral immune cells in the maintenance of neuroinflammatory process in MS and AD.

Inflammation during neurodegenerative disorders is not restricted to the CNS. Indeed, systemic inflammation has been confirmed in MS and AD, including the secretion of pro-inflammatory cytokines in peripheral domains such as the blood, cerebrospinal fluid (CSF), liver, and gut (12, 17–20). The involvement of peripheral inflammation mechanisms and immune cells in MS and AD provides strong evidence of immune dysregulation, but it is unclear whether this is a causal link in each disease or a secondary phenomenon triggered by brain injury.

Whereas, the role of humoral response has been reviewed elsewhere, here we discuss the common immune mechanisms in MS and AD and describe how neutrophils, monocytes and T cell subpopulations use similar mechanisms in MS and AD to migrate into the CNS and induce neuroinflammation and tissue damage (21). These insights suggest that interfering with shared cellular and molecular mechanisms may lead to common therapeutic approaches for MS and AD.

NEUTROPHILS: THE EMERGING PLAYERS IN MS AND AD

Neutrophils are highly reactive leukocytes with a frontline role in the maintenance of tissue homeostasis during pathological conditions, including infections and tissue damage (22). Neutrophils are highly adaptable cells due to their remarkable plasticity, and can therefore adjust their phenotype and functions in response to various environmental stimuli, triggering acute inflammatory responses (23). However, when prolonged tissue stress and damage induce sterile inflammation, neutrophils play a more subtle detrimental role, leading to chronic tissue damage that can promote pathological conditions such as autoimmunity and neurodegenerative diseases if left uncontrolled (24). These heterogeneous cells have attracted significant interest given their ability to facilitate sterile and chronic inflammation (24, 25).

Infiltrating neutrophils have been detected in the brains of MS and AD patients (10, 26). Evidence for the early involvement of neutrophils in MS includes their correlation with hyperacute lesions and altered blood-brain barrier (BBB) permeability in humans, and their involvement in the preclinical phase of EAE and acute relapses in these animal models (26, 27). Studies in AD models also suggest that neutrophils may contribute to the initial disease stages, which are characterized by increased BBB permeability, neutrophil intravascular adhesion, and invasion of the CNS (10, 11). Indeed, in animal models of both MS and AD, neutrophils accumulate in the brain before clinical manifestation, representing a major source of inflammatory mediators during early disease stages (10, 28, 29). We and others have shown that blocking neutrophil recruitment at early disease stages reduces the disease burden and tissue damage in animal models of both MS and AD (10, 30, 31). However, neutrophils continue to accumulate in the CNS throughout the disease course, suggesting these cells also play a role in disease progression and chronicity (10, 28, 29).

In MS and AD patients, the neutrophil to lymphocyte ratio (NLR) is a classical blood marker of inflammation. In MS, the NLR increases during progression and relapses, whereas in AD it correlates with cognitive impairment (32–35). In both diseases, a large proportion of circulating neutrophils is primed, as shown by the induction of activation markers such as CD11b and CD177 (36–39). Interestingly, high levels of CD11b also coincide with relapses in MS patients and correlate with the severity of the cognitive deficit in AD, suggesting that circulating neutrophils with a primed phenotype may cross the cerebral vasculature to the CNS more readily (36, 37). A similar mechanism has been proposed for CD11a/CD18 (LFA-1 or α₁β₂) in the recruitment of neutrophils in AD models (10). Furthermore, peripheral hyper-activated neutrophils secrete inflammatory mediators and intravascular neutrophil extracellular traps (NETs), thus
contributing to BBB damage and disease development (10, 24, 40) (Figure 1, Table 1).

During inflammation, the constitutive expression of CXCR2 (a chemokine receptor for the ELR\(^+\) chemokines CXCL1-3 and CXCL5-8) on mature neutrophils is strongly associated with neutrophil mobilization from the bone marrow to the bloodstream and their migration from the bloodstream to the site of injury (71). CXCL8, a CXCR2-dependent neutrophil chemoattractant, is more abundant in the plasma and CSF of MS and AD patients, and is linked to disease activity, suggesting that neutrophil migration is relevant in both diseases (44–48). Moreover, activated astrocytes produce CXCL1 (another CXCR2 ligand) at the lesion edges in EAE mice, and high levels of CXCL1, CXCL5, and CXCL8 are detected in the serum of MS patients, supporting a role for CXCR2 in the infiltration of neutrophils into the CNS in this disease (36, 44). CXCL1 is also produced by oligodendrocytes in EAE mice, attracting neutrophils into the CNS, exacerbating clinical impairment and enhancing BBB leakage (49). Interestingly, in the CNS of EAE mice, infiltrating T helper (Th) 17 cells stimulate the local release of CXCL1 and CXCL2, which leads to neutrophil recruitment (72). On the other hand, microglia in murine models of AD express CXCL1, and the levels of this chemokine in the CSF of AD patients correlate with cognitive impairment, suggesting that CXCL1 is also important in AD (50, 51) (Figure 1, Table 1). Restricting the infiltration of neutrophils using inhibitors of CXCR1 and CXCR2 has shown therapeutic efficacy in several experimental models of neuroinflammation including EAE, suggesting this may also be the case in animals with AD-like disease (73–75).

Amyloid β may also play a role in both AD and MS (76, 77). In AD brains, infiltrating neutrophils are closely associated with amyloid β deposits, and amyloid β peptides trigger the rapid integrin-dependent adhesion of neutrophils via G protein coupled receptors (10, 78). The non-random distribution of myeloperoxidase (MPO)-producing cells, presumably neutrophils, in the brain parenchyma of AD patients underlines the potential role of amyloid β as a chemoattractant that establishes a pro-inflammatory microenvironment to recruit circulating neutrophils (10). We speculate that the presence of amyloid β deposits in MS could also help to recruit neutrophils into the brain. The abundance of MPO and elastase in the blood and CNS of MS patients suggests that neutrophils may contribute to these pathological findings (56, 57). Moreover, neutrophil elastase is associated with the spread of MS lesions and clinical progression, whereas peripheral MPO activity is considered a predictor for executive function decline in AD patients (29, 46).

Neutrophil migration into the CNS during early or late phases of neuroinflammation plays a crucial role in BBB impairment. During migration, "outside-in" signaling generated following selectin and integrin engagement can induce ROS production by direct NADPH oxidase complex activation and release of other inflammation mediators such as cytokines (79–83). Moreover, it has been previously shown that intravascular neutrophil adhesion per se induces alterations in vascular permeability supporting a role for these cells in BBB breakdown (84–86). The inhibition of MPO and elastase in EAE mice reduced the number of infiltrating neutrophils, restored the integrity of the BBB, and attenuated the clinical symptoms (58, 59). MPO-producing cells were also identified in the brain parenchyma of AD patients and corresponding animal models (10). MPO and elastase are involved in the production of NETs, whose release in the CNS correlates with neuronal damage and BBB breakdown (57, 87). Indeed, the formation of NETs occurs in both MS and AD, strongly suggesting a role for neutrophils in the brain damage associated with both diseases (10, 40). Moreover, circulating neutrophils from MS and AD patients display a stronger oxidative burst, which may contribute to the formation of NETs, the activation of matrix metalloproteinases (MMPs), and therefore to BBB breakdown (40–42) (Figure 1, Table 1).

Taken together, these data suggest that activated circulating neutrophils mediate BBB damage and neurotoxicity in MS and AD by producing inflammatory mediators such as MPO and ROS, and by releasing NETs (88, 89). The blocking or inhibition of neutrophil activity could therefore achieve therapeutic benefits for both MS and AD patients (Figure 1, Table 1).

**THE ROLE OF HETEROGENEOUS MONOCYTES IN MS AND AD**

Circulating monocytes are heterogeneous and plastic innate immune cells that can promptly respond to changes in their environment. Traditionally, human monocytes are divided into three subsets: (i) classical (CD14\(^+\)/CD16\(^−\)), (ii) intermediate (CD14\(^+\)/CD16\(^+\)), and (iii) non-classical (CD14\(^−\)/CD16\(^+\)). In mice, only two subclasses of monocytes have been identified: (i) classical (CCR2\(^+\)/CX3CR1\(^−\)/Ly6C\(^hi\)), and (ii) non-classical (CCR2\(^−\)/CX3CR1\(^+\)/Ly6C\(^lo\)) (90). In addition to the differential expression of surface markers, these subsets show transcriptional and functional differences: classical monocytes are the main subset recruited to sites of infection and injury (91), whereas non-classical monocytes circulate in the blood, patrolling the vasculature (92).

Systemic alterations in monocyte subsets have been reported in humans with neurodegenerative disorders. The dysregulation of monocyte subsets in patients with RMS involves the expansion of non-classical and intermediate monocytes and the depletion of classical monocytes (61, 62). Similarly, AD patients with symptoms ranging from very mild to severe dementia accumulate non-classical and intermediate monocytes at the expense of classical monocytes (63) (Figure 1, Table 1). Although changes in circulating monocyte subsets have been confirmed across diverse CNS diseases, the meaning, causes and consequences of these alterations are still unclear. Whether different monocyte subsets correspond to developmental stages or whether each monocyte subset has a different developmental pathway remains to be determined. Given the plasticity of monocytes and their ability to respond rapidly to a wide variety of stimuli, the analysis of monocyte activation, and cytokine profiles should indicate their function and contribution to peripheral inflammation during neurodegeneration. Indeed, circulating monocytes in MS and AD patients shift toward
FIGURE 1 | Schematic representation of innate immune mechanisms in MS and AD. Non-classical monocytes and neutrophils are expanded in peripheral blood and the higher neutrophil-lymphocyte ratio (NLR) correlates with the clinical symptoms of each disease. In addition, these cells express canonical activation markers (HLA-DR and CD11b) and release inflammatory mediators, such as pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), myeloperoxidase (MPO), and neutrophil extracellular traps (NETs). Chemokine binding stimulates monocytes and neutrophils to infiltrate the CNS by chemotaxis (mediated by CCR2 and CXCR2, respectively). Within the CNS, monocytes show impaired phagocytosis and secrete the pro-inflammatory cytokines IL-1β, TNF-α, IL-6, and IL-8, thus fueling the inflammatory response. Similarly, infiltrating neutrophils contribute to neuroinflammation and tissue damage by releasing NETs, reactive oxygen species (ROS), MPO, and matrix metal proteinases (MMPs).

a pro-inflammatory phenotype (63, 64) (Figure 1, Table 1). Particularly, in MS patients, isolated monocytes were shown to produce more IL-1β, TNF-α, IL-6, and IL-8 under basal conditions (61). Similarly, unstimulated monocytes from patients with dementia express higher levels of IL-6, IL-1β, and TNF-α mRNA (63) (Figure 1), suggesting a pro-inflammatory phenotype in AD. Interestingly, IL-8, and TNF-α mRNA levels also increase when human monocyte-like cell line THP-1 is incubated with plasma from AD patients or transgenic mice with AD-like disease, compared to plasma from healthy human controls or wild-type mice, respectively (65). This provides evidence that systemic inflammatory conditions affect the function of circulating monocytes.

Monocytes can migrate into tissues and differentiate into macrophages, making them important players in brain homeostasis. However, the correct identification of these cells in the CNS has proved challenging due to the similarities between microglia and monocyte-derived macrophages, especially during inflammation when the surface markers change. This has been addressed by advances in genome editing and cell tracing technology, leading to the identification of CCR2 and CX3CR1 as markers of murine classical monocytes and microglia, respectively (93). In this context, establishing how circulating monocytes are recruited to the inflamed brain can contribute significantly to the understanding of pathophysiology in MS and AD. Studies in murine models revealed the essential role of CCR2, a chemokine receptor involved in mononuclear trafficking at inflammation sites (94). In the EAE model of MS, classical monocytes were found to infiltrate the inflamed brain and the ablation of CCR2 blocked this process, suggesting a key role for
this receptor in the recruitment of monocytes to the CNS during EAE (66). The same phenomenon has been observed in AD mice, where the loss of CCR2 reduces the number of monocytes in the brain (67, 68) (Figure 1, Table 2). Together, these findings suggest that classical monocytes are the main subset that invades the CNS in neuroinflammatory conditions such as MS and AD and that CCR2 plays a fundamental role in the recruitment of these cells into the CNS. Interestingly, while CCR2 blockade in EAE has a beneficial effect, inhibition of this receptor in AD models increases Aβ deposition and worsens memory deficits, suggesting a decreased expression of CCR2 could play a potential role in the etiology of AD. Accordingly, the number of monocytes is lower in AD mouse models than controls, mostly due to the depletion of CCR2+ monocytes, suggesting these cells are severely impaired in AD (140). Also, in AD patients, CCR2 expression decreases in circulating monocytes whereas the levels of plasma CCL2 were increased, suggesting systemic immunologic dysfunction CCR2-CCL2 axis (141, 142) (Figure 1). Although mouse models of MS confirm the close involvement of monocytes in disease pathogenesis, clinical trials using CCR2 antagonists did not demonstrate efficacy (EU Clinical Trials: https://www.clinicaltrialsregister. eu/ctr-search/search?query=2004-000073-64). Indeed, CCR2+ monocytes can be immunosuppressive, they replenish important macrophage populations, and they play pivotal roles during infection, potentially explaining the lack of positive results following a CCR2 therapeutic blockade in MS (68, 143, 144).

Infiltrating monocytes and resident microglial cells can both react to inflammatory stimuli and mount an immune response in the CNS during neurodegenerative diseases (144). Indeed, monocytes not only infiltrate the CNS parenchyma but also colonize the meninges in EAE mice (145). Furthermore, monocyte infiltration begins at the onset of the disease and continues to increase until the disease peak, suggesting a role for these cells in disease induction and progression (145). Moreover, monocyte-derived cells infiltrating the CNS are major players in antigen presentation during EAE and recent studies identified several subtypes of infiltrating monocytes/myeloid cells in the CNS with different transcriptional landscapes during the acute and chronic stages of EAE (146). Similarly, single-cell studies revealed disease-specific transformations across several types of brain-associated phagocytes in murine models of AD, but the existence of common signatures between EAE/MS and AD is unclear (147). In AD mice, circulating monocytes have been shown to invade the brain and reduce amyloid β burden, suggesting a beneficial role for these cells in AD (148). Also, patrolling monocytes have been described to crawl onto the luminal walls of amyloid β-positive veins, suggesting their ability to target and clear amyloid β (149). The same applies to perivascular macrophages in another mouse model of AD, in which their depletion led to an increased accumulation of amyloid β deposits in blood vessels (150). Brain macrophages are not only involved in the clearance of CNS debris or amyloid β, but also play an important role in regulating iron levels. Extracellular accumulation of iron during neurodegeneration can be attributed to an array of processes including oligodendrocyte and myelin degeneration (151, 152). Indeed, increased iron deposits in white matter lesions have been shown in both MS and AD, and iron accumulation correlates with cognitive deficits (153, 154). Interestingly, the deposition of iron observed in MS was often co-localized with microglia/macrophages, which express the transferrin receptor, a main iron influx protein. By capturing iron and, therefore, preventing Fenton reactions and the creation of oxygen radicals, macrophages play an important regulatory function in the inflamed brain during MS (155, 156). In AD, however, there is limited information on iron uptake by macrophages, although recent evidence suggests that stimulation of microglia with Aβ increases the uptake of non-bound iron by these cells (157).

However, although monocytes infiltrate the brain and, to some degree, remove debris, iron and amyloid β, these cells in mice with AD-like disease are ineffective in clearing amyloid β in the diseased brain and their peripheral phenotype changes...
**TABLE 2 |** Summary of common pathways in the adaptive immune system during the development of MS and AD.

| Common mechanisms | MS | AD |
|-------------------|----|----|
| CD4+ cells infiltrate CNS | (95) (human) | (99) (human) |
| and serum level of IL-17 | (96) (human) | (99) (human) |
| CD4+ T cells interact with microglia expressing MHC-II at high levels | (108) (human) | (109) (mouse) |
| CD4+ T cells work along the gut–brain axis to modify cognitive functions | (112) (mouse) | (114) (mouse) |
| CD8+ T cells infiltrate the CNS and trigger detrimental effects | (115) (human) | (103) (human) |
| Increased proportion of circulating CD8+ T cells | (119) (human) | (121) (human) |
| Circulating CD8+ T cells show a primed-activated phenotype | (120) (human) | (123) (human) |
| Clonally expanded CD8+ TEMRL cells | (126) (human) | (127) (human) |
| Lower number of circulating CD4+ CD25+ FoxP3+ cells | (128) (human) | (130) (human) |
| Treg cells with impaired regulatory activity | (131) (human) | (133) (human) |
| Depletion of Treg cells associated with worst outcomes | (135) (mouse) | (138) (mouse) |

CD4+ T lymphocytes in MS and AD

CD4+ T cells infiltrate both the white and gray matter of MS patients, and similar observations have been reported in AD brains (95–100) (Table 2). Pathogenic CD4+ T cells in MS and EAE have been subtyped by cytokine profiling, revealing Th1 cells that produce IFN-γ and Th17 cells that produce IL-17. Both Th1 and Th17 cells are key components of the autoimmune inflammatory process during the development of MS, and they may fulfill analogous roles in AD. Following CNS invasion, Th1 and Th17 cells produce inflammatory mediators and cytokines to establish and/or maintain an inflammatory environment that promotes neuronal loss, a common feature of MS and AD that positively correlates with the disease course (167, 168). In particular, the infiltration of Th17 cells into the CNS of MS patients increases the concentration of IL-17 in the blood and CSF and the number of Th17 cells found in these compartments (101, 102, 169). Similarly, IL-17 also accumulates to higher levels in the serum of AD patients compared to healthy controls and has been proposed as part of a blood-based signature to distinguish individuals with AD from healthy subjects (104, 170). The population of circulating Th17 cells has also been shown to increase in MCI patients compared to both age-matched controls and AD patients, suggesting that Th17 cells may be involved in the early stages of AD (103) (Table 2). Intriguingly, EAE mice modified to abolish IL-17 production, as well as AD models treated with neutralizing antibodies against IL-17, show delayed clinical progression, confirming the harmful effects of IL-17 in EAE and suggesting that Th17 cells also contribute to the progression of AD (171).

CD4+ T lymphocytes appear to invade the CNS of AD and MS patients using common molecular pathways, emphasizing the common leukocyte recruitment mechanisms in these two diseases. For example, several studies in MS/EAE have shown that α4-integrins play a key role in the trafficking of Th cells (105, 106). EAE...
progression is delayed following the selective deletion of α4-integrin genes in T cells and MS progression is delayed by treatment with the α4-integrin-blocking humanized antibody natalizumab (172, 173). We and others recently demonstrated a similar molecular mechanism controlling the infiltration of Th cells in AD models (31, 107). We observed the stronger expression of α4-integrins on circulating CD4⁺ T cells in an AD mouse model compared to age-matched controls, along with an increase in the abundance of CD4⁺ cells in the brains of AD mice (31) (Figure 2, Table 2). Importantly, blocking α4-integrins inhibited the adhesion of circulating leukocytes in the brain microcirculation and reduced the neuropathological hallmarks of AD, highlighting the potential for a therapeutic approach that is similar in efficacy to the use of natalizumab in MS patients (172, 173).

In EAE models, lymphocytes are presented with antigens in the periphery before CNS invasion. Indeed, T-cell priming begins in secondary lymphoid organs and leads to the activation and expansion of neuroantigen-reactive T cells that later infiltrate the CNS, where they re-encounter their cognate antigen (174). Within the CNS, microglial cells may promote the proliferation and activation of CNS-reactive T lymphocytes (174, 175). In both MS and AD, activated microglia express the main major histocompatibility complex class II molecule (MHC-II) as well as co-stimulatory molecules such as CD40, CD80, and CD86, which equip the microglia for antigen presentation to infiltrating T cells, creating a vicious cycle that promotes neuroinflammation and potentially antigen presentation (108–111) (Figure 2, Table 2). As a result, the pro-inflammatory environment that can activate CD4⁺ T cells is continuously boosted, and may promote neuronal damage in both MS and AD (Figure 2).

Although CD4⁺ T cells are considered pathogenic in several CNS disorders, they may also provide beneficial functions in AD, ranging from tissue protection to regeneration (176). In AD models, amyloid β-reactive T cells effectively target amyloid β plaques in the brain, enhancing phagocytosis by microglia and leading to neuronal repair (177). Furthermore, Th1 cells injected into the ventricles of AD mice were able to induce the differentiation of microglia (protective MHCI-II subtype), boosting the capacity for amyloid β clearance (111). Despite these tantalizing results, a protective role for CD4⁺ T cells has yet to be confirmed in AD, and immunotherapeutic approaches based on amyloid β have not achieved efficacy in clinical trials (178).

**Treg Cells and Their Failure to Control Inflammation in MS and AD**

Treg cells fulfill an active regulatory role in peripheral tolerance mechanisms, preventing the onset of autoimmunity and limiting chronic inflammation. They downregulate the activities of various immune cells, including effector T cell functions and proliferation, by the secretion of immunosuppressive cytokines (including TGF-β, IL-10 and IL-35) and/or by direct cytotoxicity and the induction of apoptosis (through the release of granzyme B and perforin 1) (179–181). Treg cells also cause indirect immunosuppression via cytotoxic T lymphocyte antigen 4 (CTLA4), CD39, and CD73, and disrupt the metabolism of the effector T cells by modulating the maturation and/or function of the dendritic cells (DCs) required for their activation (182).

Dysfunctional Treg cells have been linked to neuroinflammatory conditions, and the analysis of peripheral blood demonstrates how Treg cells can contribute during neurodegenerative diseases. Treg cells have recently been shown to infiltrate the brain and suppress astrogliosis by producing amphiregulin in a model of ischemic stroke, but their role during AD and MS is unclear (183). Several studies have shown that the number of circulating Treg cells declines in both MS and AD patients compared to matched controls, suggesting that their dysregulation in the periphery reduces their immunosuppressive capacity and promotes uncontrolled inflammation (128–130). Indeed, Treg cells isolated from the peripheral blood of MS patients show an impaired ability to modulate CD4⁺ T cell proliferation and IFN-γ production (131). Compared to healthy controls, RRMS patients also produce more Th1-like Foxp3⁺ T cells that secrete IFN-γ and show a limited reduced immunosuppressive capacity (132). Similarly, the immunosuppressive functions of Treg cells in AD patients are compromised compared to both healthy controls and subjects with MCI (133, 134) (Table 2). These data are supported by animal models discussed below, where Treg cells appear to be important in both EAE and AD, especially during the early phases of both diseases, but at later stages they are depleted and/or dysfunctional and are therefore unable to control the inflammatory response.

The depletion of Treg cells by anti-CD25 antibodies in EAE mice increased the severity of the disease, boosting the production of IL-17 and T cell infiltration (135). In line with the protective role of Treg cells, the transplantation of neural stem cells in EAE mice induces remyelination by expanding the Treg cell population (136, 137). Similarly, the depletion of Treg cells in mice with AD-like disease is associated with the premature loss of cognitive functions and a worse outcome (138). Furthermore, low doses of IL-2 increased the number of Treg cells in the peripheral blood and lymphoid organs of these mice, restoring their cognitive ability (138). Similar results were reported by others, showing that Treg cell depletion for 4 months during the early stages of AD-like disease aggravated the cognitive deficits and increased the deposition of amyloid β plaques (139). In these studies, the adoptive transfer of purified Treg cells improved cognitive functions and reduced the amyloid β burden (139) (Table 2). Curiously, Treg cell depletion during the late disease stage in an aggressive model of amyloidosis also conferred a beneficial effect, presumably by boosting the immune response, suggesting that the effect of Treg cells on AD-like disease is stage-dependent (184). Taken together, these results suggest that Treg cells play a key role in controlling the development of neuroinflammation in both MS and AD (Figure 2). Therapeutic strategies aiming to exploit the immunosuppressive properties of Treg cells may therefore help to address both pathologies.
clear. Nevertheless, cytotoxic lymphocytes play a prominent role in the development of many viral and non-viral diseases by the direct killing of infected or otherwise modified cells. Following antigen recognition, cytotoxic T cells classically induce apoptosis in target cells via two alternative mechanisms: (i) FasL-CD95 (FasR) binding to activate caspase, and (ii) the release of granzyme B and perforin. CD8$^+$ effector T cells may also cause cellular damage indirectly by secreting the pro-inflammatory cytokines TNF-$\alpha$ and IFN-$\gamma$ (185). During immune responses, CD8$^+$ T cells interact with CD4$^+$ T cells to optimize the precision...
of CD8\(^+\) T cell effector functions after priming by enhancing their cytotoxicity and capacity for migration (186).

CD8\(^+\) T cells have received less attention than CD4\(^+\) T cells in MS and EAE, but it is now well-established that CD8\(^+\) T cells are more activated in the periphery and can infiltrate active lesions, contributing to the increasing severity of MS symptoms (115, 116, 187). Furthermore, clonally expanded cytotoxic T cells exacerbate brain inflammation in EAE initiated by CD4\(^+\) T cells, suggesting that CD8\(^+\) T cells may be primarily responsible for the observed cerebral alterations (187) (Table 2).

The role of CD8\(^+\) T cells in AD is less clear, although these cells were first detected in the brains of AD patients almost 20 years ago (100). The infiltration of CD8\(^+\) T cells into the brains of AD patients and corresponding mouse models also correlates with disease worsening, suggesting these cells may be involved in disease development (98, 100, 118). CD8\(^+\) T cells were shown to accumulate in an active state in the peripheral blood of MS patients and in AD patients with dementia (119–121) (Table 2). The comparison of blood samples from AD patients and healthy controls revealed the production of more pro-inflammatory cytokines by cytotoxic T cells in the AD patients and a greater proportion of activated HLA-DR\(^+\) CD8\(^+\) T cells (117, 125). Similarly, circulating CD8\(^+\) T cells from patients in the acute phase of RRMS showed increased adhesion to brain venules compared to control cells, further highlighting their activated phenotype (122). In line with this, the characterization of CD8\(^+\) T cells from the CSF and brain tissue of MS patients showed their activated/memory phenotype (123, 124) (Table 2). Notably, a higher frequency of CD8\(^+\) effector memory T cells was detected in the CSF of AD patients with dementia compared to controls, suggesting CD8\(^+\) T cells contribute to brain damage in both AD and MS with similar underlying mechanisms (117, 121).

The extravasation of cytotoxic T cells in the brain promotes the brain damage caused by CD8\(^+\) T cells and appears to be mediated by LFA-1 integrin (CD11a/CD18) in both MS and AD (Figure 2). LFA-1 is a marker of leukocyte activation that binds ICAM-1, which is overexpressed by endothelial cells in several neuroinflammatory conditions (10, 188). CD11a expression was shown to increase on clonally expanded CD8\(^+\) T cells in MS patients, promoting their transmigration into the brain (116). Without referring to specific T cell populations, previous studies have shown that the transfer of encephalitogenic CD11a\(^{-/-}\) T cells to wild-type mice reduces the severity of EAE, suggesting that LFA-1 also facilitates the migration of CD8\(^+\) T cells in this disease (189). The presence of LFA-1\(^+\) T cells infiltrating the hippocampus of AD patients suggests a role for LFA-1 also in AD (100). This is consistent with the increase in Ilg2 (LFA-1) mRNA levels in the hippocampus of a mouse model of tauopathy (190). Finally, the strong upregulation of ICAM-1 was observed in cortical and hippocampal brain regions invaded by CD3\(^+\) T cells in mouse models of AD, suggesting that LFA-1 also promotes T cell migration into the AD brain (10, 191). Further studies are needed to confirm that LFA-1 is required for the trafficking of CD8\(^+\) T cells in AD, but given that LFA-1 is required for cytotoxic T cell activation, maturation, immuno-synapse stabilization and functioning, this integrin is likely to play a key role in driving CD8\(^+\) responses in AD (192).

Another important topic in the context of MS and AD is the antigenic specificity and clonal origin of CNS-infiltrating CD8\(^+\) T cells. The analysis of lymphocytes collected from the blood, CSF and brain lesions of many MS patients has shown that CD8\(^+\) T cells undergo clonal expansion, suggesting that they are activated by specific antigens (115, 123). Other studies in MS patients have identified a population of CD8\(^+\) T cells specific for myelin proteins, presenting an activated/memory phenotype due to in situ antigen presentation (96, 119, 120, 193). Tau protein may fulfill a similar role in AD, representing the potential link between cytotoxic T cells and disease development. Indeed, CD8\(^+\) T cells accumulate in the hippocampal regions of a mouse model of tau pathology, apparently via a tau-driven transmigration mechanism (190). A correlation between tau pathology and the infiltration of CD3\(^+\) T cells was revealed by the immunohistochemical analysis of post-mortem AD brains, further supporting the potential association between tau and CD8\(^+\) T cell-dependent pathology in AD (194).

Clonally expanded CD8\(^+\) T\(_{EMRA}\) cells were recently identified in the CSF of AD patients, suggesting that antigen-experienced cytotoxic cells patrol the intrathecal space of AD patients. Interestingly, as already shown in MS patients, CD8\(^+\) T cells in the CSF were expanded predominantly against Epstein-Barr viral antigens, suggesting a new link between EBV, CD8\(^+\) T cells and AD (117, 127). CD8\(^+\) T\(_{EMRA}\) cells accumulated not only in the CSF of AD patients, but also in the blood of RRMS and SPMS patients, suggesting these cells contribute to the progression of both AD and MS by promoting chronic inflammation (126) (Table 2). More detailed studies are required to determine precisely how this cell population fits into the complex pathogenesis of neurodegenerative disorders.

The pro-inflammatory nature of CD8\(^+\) T\(_{EMRA}\) cells is strictly associated with IFN-\(\gamma\) secretion, which occurs mainly during active proliferation (195). One of the harmful functions of IFN-\(\gamma\) is the ability to favor neuronal killing by CD8\(^+\) T cells via the FasR-FasL pathway (185). Accordingly, previous studies have shown that the overexpression of MHC-I on neurons exposed to IFN-\(\gamma\) promotes neuronal damage by CD8\(^+\) T cells via TCR-MHC-I binding (196). Interestingly, MHC-I has been detected on neurons in both hippocampal and cortical brain regions, which are heavily damaged in AD (196). Similarly, CD8\(^+\) T cells in chronic and active MS plaques were found marginally in contact with oligodendrocytes, astrocytes and neurons expressing MHC-I at high levels (96, 96, 193). These results indicate that CD8\(^+\) T cells producing IFN-\(\gamma\) enhance the expression of MHC-I on neurons in MS and AD, and could therefore promote the brain alterations associated with the progression of both diseases (Figure 2). In conclusion, CD8\(^+\) T cells appear to drive the development of both MS and AD by sustaining chronic inflammation and directly causing CNS injury.

The Gut–Lymphocyte–Brain Axis in AD and MS

Several clinical and preclinical studies have shown that the course of MS and AD is influenced by the commensal gut
microbiome, highlighting the interplay between the brain, gut microbes, intestinal barrier and immune system (197, 198). Indeed, fecal and mucosa-associated gastrointestinal tract microbes differ between AD patients and healthy controls, and recent studies comparing germ-free animals and those exposed to pathogenic bacteria, probiotics or antibiotics suggested a role for gut microbes in host cognitive functions and the development of AD-like neuropathological features (113, 199–202). Many studies have also focused on the role of gut microbes in MS and EAE (112, 203–208). These studies suggest that altering the gut microbiome with antibiotic cocktails or probiotics can attenuate the disease course by modulating regulatory immune responses (198). Although many of the microbes and metabolites in the gut–CNS axis have been identified, little is known about the underlying cellular and molecular immune mechanisms. In MS, the balance between pro-inflammatory myelin-reactive effector cells and anti-inflammatory immune elements controlling the formation of CNS lesions is continuously influenced by the gut. Indeed, both monocytes and gut-resident macrophages influence the gut-dependent activation of CD4+ T cells, which promotes Th1 polarization and IFN-γ secretion (209). Gut microbes and their metabolites also regulate T cell-mediated adaptive immune responses. For example, specific bacteria such as Akkermansia muciniphila and Acinetobacter calcoaceticus are associated with MS, inducing a pro-inflammatory T cell phenotype that perpetuates autoimmune responses, whereas segmented filamentous bacteria, symbiotic colonizers of the small intestine, induce Th17 differentiation and activation to promote the development of EAE (210, 211) (Figure 2). In contrast, CNS demyelination and inflammation during EAE is inhibited by gut flora rich in the commensal bacterium Bacteroides fragilis, which promotes the expansion of Treg cells expressing the ectonucleotidase CD39 and their migration into the CNS (212) (Figure 2). A recent innovative study in SPMS patients confirmed a role for the gut–brain axis in MS patients, showing the depletion of a subset of circulating memory CD4+ T cells expressing the gut-homing chemokine receptor CCR9 and the α4β7 adhesion molecule and a tendency to switch from a regulatory to a pro-inflammatory phenotype that produces more IFN-γ and IL-17 (213). Recently, gut dysbiosis in MCI patients was shown to increase phenylalanine and isoleucine levels, correlating with an increase in the number of circulating Th1 cells (114) (Figure 2). Interestingly, naïve CD4+ T cells exposed to phenylalanine or isoleucine acquire an activated Th1 phenotype, and the oral treatment of mouse models of AD with the prebiotic oligosaccharide GV-971 (which suppresses gut dysbiosis) reduced the concentration of phenylalanine and isoleucine, resulting in the amelioration of neuroinflammation and cognitive impairment (114).

Collectively, these data show that gut dysbiosis contributes to peripheral immune cell dysregulation and triggers an enhanced inflammatory immune response. The gut–brain axis may therefore provide an appropriate target for immunomodulatory therapy in both diseases.

CONCLUSIONS

Neurodegenerative diseases are increasing in prevalence and socioeconomic impact. The identification of common cellular and molecular mechanisms involving the immune system may provide more insight into pathogenesis, leading to potential common therapeutic strategies. Several genome-wide association studies (GWAS) in both MS and AD patients have revealed associations between these diseases and gene expression in peripheral adaptive and innate immune cells, suggesting common immune mechanisms controlling neuroinflammation and neurodegeneration (214–216). Moreover, functional studies in vitro and in vivo have revealed shared detrimental molecular mechanisms in peripheral leukocytes, representing potential common therapeutic targets for the control of immune responses in MS and AD (217–219). One clear example of such a shared molecular mechanism is represented by α4 integrins, which can be targeted in both MS and AD. Indeed, the therapeutic effect of α4 integrins in EAE and MS has been corroborated by recent studies showing that targeting these adhesion molecules reduces neuroinflammation and the neuropathological hallmarks of AD (31). Moreover, reducing BBB breakdown that characterizes several neurodegenerative disorders, including MS and AD, could be considered as another common possible therapeutic strategy in reducing not only the influx of various neurotoxic agents, but also the recruitment of immune cells into the CNS (220, 221). By using animal models of both MS and AD, it was indeed demonstrated that targeting BBB pathways to preserve vascular integrity, ameliorates the course of brain pathology (222, 223). Therefore, a deeper understanding of the activation status of peripheral innate and adaptive immune cells in the blood, their trafficking mechanisms, CNS pathogenic signatures, and neurotoxic effects, may lead to the discovery of new common biomarkers of MS and AD that could facilitate the identification of common therapeutic strategies for both diseases.

AUTHOR CONTRIBUTIONS

All authors contributed to the literature search and writing the review.

FUNDING

This work was supported in part by the European Research Council (ERC) advanced grant no. 695714 IMMUNOALZHEIMER and the ERC Proof of Concept grant no. 693606 IMPEDE (to GC); Alzheimer’s Drug Discovery Foundation (ADDF), USA (to GC); Fondazione Italiana Sclerosi Multipla (FISM), Genoa, Italy [Cod. 2013/IR/21 (to BR) and Cod. 2019/PR-single/044 (to EZ)]; University of Verona, Italy (FUR) (to GC); INVITE European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 754345 (to BS-L); Fondazione Umberto Veronesi post-doctoral fellowship 2019 and 2020 (to EZ).
REFERENCES

1. Rotstein DL, Chen H, Wilton AS, Kwong JC, Marrie RA, Gozdyra P, et al. Temporal trends in multiple sclerosis prevalence and incidence in a large population. Neurology. (2018) 90:1435–41. doi: 10.1212/WNL.0000000000005331

2. Lopez OL, Keller LH. Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer’s disease and other dementias. Handb Clin Neurol. (2019) 167:339–48. doi: 10.1016/B978-0-12-804766-8.000009-1

3. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. (2017) 13:25–36. doi: 10.1038/nrneurol.2016.187

4. Stephenson J, Nutma E, van der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. (2018): 154:204–19. doi: 10.1111/imm.12922

5. Rahmanzadeh R, Bruck W, Minagar A, Sahraian MA. Multiple sclerosis: missing pieces of an old puzzle. Rev Neurosci. (2018) 30:67–83. doi: 10.1515/reneuro-2018-0002

6. Yoles E, Hauben E, Palgi O, Agrawon E, Gothilf A, Cohen A, et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci. (2001) 21:3740–8. doi: 10.1523/JNEUROSCI.21-11-037040.2001

7. Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. (2014) 33:7–22. doi: 10.1002/embo.201386609

8. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. (2015) 523:337–41. doi: 10.1038/nature14432

9. Ransohoff RM, Engellard H. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. (2012) 12:623–35. doi: 10.1038/nn13265

10. Zanero E, Pietronigro E, Della Bianca V, Piccentino G, Marongiu L, Budui S, et al. Neutrophils promote Alzheimer’s disease-like pathology and cognitive decline via FcαR-I integrin. Nat Med. (2015) 21:880–6. doi: 10.1038/nm.3913

11. Zanero E, Piccentino G, Constantin G. The blood-brain barrier in Alzheimer’s disease. Neurobiol Dis. (2017) 107:41–56. doi: 10.1016/j.nbd.2016.07.007

12. Prinz M, Priller J. The role of peripheral immune cells in neurodegenerative diseases. Nat Rev Neurol. (2019) 154:204–19. doi: 10.1038/s41577-019-0141-8

13. Vainchtein ID, Molofsky AV. Astrocytes and microglia: in sickness and in health. Trends Immunol. (2011) 32:9–22. doi: 10.1016/j.it.2010.12.004

14. Wang X, Zhu M, Hjorth E, Cortes-Toro V, Eyjolfsdottir H, Graff C, et al. Specialized pro-resolving lipid mediators are differentially altered in demyelinating neuroinflammatory diseases. J Immunol. (2014) 193:2438–54. doi: 10.4049/jimmunol.1400401

15. Kostic M, Djopalic T, Zivanovic S, Zivkovic N, Cvetanovic A, Stoijnov I, et al. IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis. Scand J Immunol. (2014) 79:181–6. doi: 10.1111/sj.12147

16. Wu F, Cao W, Yang Y, Liu A. Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice. Histochim Cell Biol. (2010) 133:313–22. doi: 10.1007/s00418-009-0673-2

17. Rumble JM, Huber AK, Krishnamoorthy G, Srinivasan A, Giles DA, Zhang X, et al. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med. (2015) 212:23–35. doi: 10.1084/jem.20141015

18. Miller NM, Wang J, Tan Y, Dittel BN. Anti-inflammatory mechanisms of IFN-gamma studied in experimental autoimmune encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis. Front Neurosci. (2015) 9:287. doi: 10.3389/fnins.2015.00287

19. Pietrogrino E, Zanero E, Bianca VD, Dusi S, Terrabuio E, Iannotti G, et al. Blockade of alpha4 integrins reduces leukocyte-endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer’s disease. Sci Rep. (2019) 9:12055. doi: 10.1038/s41598-019-45388-x

20. Koyuncu ME, Yesil Y, Ozturk ZA, Kizilaslanoglu C, Eftal S, Halil M, et al. The evaluation of neutrophil-lymphocyte ratio in Alzheimer’s disease. Dement Geriatr Cogn Disord. (2012) 34:69–74. doi: 10.1159/000341583

21. Demirci S, Demirci S, Kutluhan S, Koyuncuoglu HR, Yurekli VA. The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int J Neurosci. (2016) 126:700–6. doi: 10.3109/09629359.2015.1050492

22. Biaagard AK, Pihl-Jensen G, Frederiksen JL. The neutrophil-to-lymphocyte ratio as disease activity marker in multiple sclerosis and optic neuritis. Mult Scler Relat Disord. (2017) 18:213–7. doi: 10.1016/j.msard.2017.10.009

23. Dong X, Nao J, Shu X, Zeng D. Predictive value of routine peripheral blood biomarkers in Alzheimer’s disease. Front Aging Neurosci. (2019) 11:332. doi: 10.3389/fnagi.2019.00332

24. Ziaber J, Pasnik J, Baj Z, Pokoca L, Chmielewski H, Tchorzewski H. The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis. Mediators Inflamm. (1998) 7:335–8. doi: 10.1080/09629359890857

25. Scali C, Prosperi C, Bracco L, Piccini C, Baronti R, Ginestroni A, et al. Neutrophils CD11b and fibroblasts PGE(2) are elevated in Alzheimer’s disease. Neurobiol Aging. (2002) 23:523–30. doi: 10.1016/S0197-4501(01)00346-3

26. Cordiglieri C, Baggi F, Bernasconi P, Capetis D, Faggiani E, Consonni A, et al. Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. Clin Immunol. (2016) 173:133–46. doi: 10.1016/j.clim.2016.10.002

27. Le Page A, Lamoureux J, Bourgade K, Frost EH, Pawelec G, Witkowska J, et al. Polymorphonuclear neutrophil functions are differentially altered in amnestic mild cognitive impairment and mild Alzheimer’s disease patients. J Alzheimers Dis. (2017) 59:62–32. doi: 10.3233/JAD-170124

28. Naegle M, Tillack K, Reinhardt S, Schilling S, Martin R, Sospenda M. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol. (2012) 242:60–71. doi: 10.1016/j.jneuroim.2011.11.009
41. Vitte J, Michel BF, Bongrand P, Gastaut J. Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases. J Clin Immunol. (2004) 24:683–92. doi: 10.1007/s10875-004-6243-4

42. Dong Y, Lagarde J, Xicota L, Di Ludovico F, Viti R, Angeleri VA, et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paroxonase activity. Mult Scler. (2005) 11:677–82. doi: 10.1193/135248505s12400a

43. Bawa KK, Krance SH, Herrmann N, Manoukian K, Groschen S, et al. Increased expression of CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol. (2004) 155:161–71. doi: 10.1016/j.neuroim.2004.06.008

44. Tillack K, Naegele M, Haueis C, Schippling S, Wandinger KP, Martin R, et al. Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity. J Neuroimmunol. (2006) 178:156–60. doi: 10.1016/j.neuroim.2006.05.026

45. Chick SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, et al. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuro. (2008) 59:668–80. doi: 10.1101/neo.2008.07.033

46. McCauley MC, Powers JM, Bias WB, Schmeckpeper BJ, Segal AH, Gowda VC, et al. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinating lesions of X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroinflammation. (1997) 15:74–82. doi: 10.1186/1742-209X-15-74

47. Kim Y, Fong Y, Chu T, Chen P, He K, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci. (2020) 20:5709–14. doi: 10.1523/JNEUROSCI.20-15-05709.2000

48. Minohara M, Matsuoka T, Li W, Osoegawa M, Ishizu T, Ohyagi Y, et al. Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity. J Neuroimmunol. (2006) 178:156–60. doi: 10.1016/j.neuroim.2006.05.026

49. Tillack K, Naegel M, Hauens C, Schilling S, Wadinger KP, Martin R, et al. Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. J Neuroimmunol. (2013) 261:108–19. doi: 10.1016/j.neuroim.2013.05.004

50. Zhang H, Ray A, Miller NM, Hartwig D, Pritchard KA, Dittel BN. Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity. J Neurochem. (2016) 136:826–36. doi: 10.1111/jnc.13426

51. Yu G, Zheng S, Zhang H. Inhibition of myeloperoxidase by N-acetyl l-lysyllysyrysteine amide reduces experimental autoimmune encephalomyelitis–induced injury and promotes oligodendrocyte regeneration and neurogenesis in a murine model of progressive multiple sclerosis. Neuroreport. (2018) 29:208–13. doi: 10.1097/WRN.0000000000001948

52. Gallhaar S, Sunnemark D, Eriksson H, Olson L, Galter D. Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease. Cell Tissue Res. (2017) 369:445–54. doi: 10.1007/s00441-017-2626-8

53. Waschbisch A, Schrauder S, Schraudner D, Sammet L, Welsker B, Melms A, et al. Pivotal role for CD16+ monocyes in immune surveillance of the central nervous system. J Neuroimmunol. (2016) 196:1558–67. doi: 10.1016/j.jimmunol.1501960

54. Haschka D, Tymoszuk P, Bteh P, Petzer V, Berek K, Theurl I, et al. Expansion of neutrophils and classical and nonclassical monocytes as a hallmark in relapsing-remitting multiple sclerosis. Front Immunol. (2020) 11:594. doi: 10.3389/fimmu.2020.00594

55. Thome AD, Faridar A, Beers DR, Thonhoff JR, Zhao W, Wen S, et al. Functional alterations of myeloid cells during the course of Alzheimer's disease. Mol Neurodegener. (2018) 13:61. doi: 10.1186/s13024-018-0293-1

56. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage in relapsing-remitting multiple sclerosis. J Exp Med. (2013) 131:524–34. doi: 10.1084/jem.201302053.x

57. Wolfe H, Mela V, Minogue AM, Miller AM, McGuigan C, Williams L, et al. Monocytes exposed to plasma from patients with Alzheimer’s disease undergo metabolic reprogramming. Neurosci. Res. (2019) 148:54–60. doi: 10.1016/j.neures.2019.01.001

58. Mildner A, Mack M, Schmidt H, Bruck W, Djukic M, Zabel MD, et al. CCR2+ Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain. (2009) 132(Pt 9):2487–500. doi: 10.1093/brain/awp144

59. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. (2007) 13:432–8. doi: 10.1038/nm1555

60. Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci. (2011) 31:6208–20. doi: 10.1523/JNEUROSCI.0299-11.2011

61. Natraj MS, Komori M, Kosa P, Johnson KR, Wu T, Franklin RJ, et al. Pivotal role for CD16+ monocytes. Front Immunol. (2015) 2:1071–84. doi: 10.1002/acn3.260

62. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis. (2005) 7:221–32; discussion 255–62. doi: 10.3233/JAD-2005-7304

63. Wengner AM, Pitchford SF, Furze RC, Rankin SM. The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation. Blood. (2008) 111:42–9. doi: 10.1182/blood-2007-07-099648

64. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med. (2008) 205:1535–41. doi: 10.1084/jem.20081059

65. Kerstetter AE, Podavani-Claudio DA, Bai L, Miller RH. Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis. Exp Neurol. (2009) 220:44–56. doi: 10.1016/j.expneurol.2009.07.010

66. Semple BD, Bye N, Ziebel JM, Morganti-Kossmann MC. Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury. Neurobiol Dis. (2010) 40:394–403. doi: 10.1016/j.nbd.2010.06.015

67. Hosking MP, Lane TE. ELR (+) chemokine signaling in host defense and disease in a viral model of central nervous system disease. Front Cell Neurosci. (2014) 8:165. doi: 10.3389/fncel.2014.00165

68. Chandra A. Role of amyloid from a multiple sclerosis perspective: a literature review. Neuroimmunomodulation. (2015) 22:343–6. doi: 10.1159/000375309
77. Stampacchini Bassi M, Garofalo S, Marfia GA, Giliio L, Simonelli I, Finardi A, et al. Amyloid-beta homeostasis bridges inflammation, synaptic plasticity deficits and cognitive dysfunction in multiple sclerosis. Front Mol Neurosci. (2017) 10:390. doi: 10.3389/fnmol.2017.00390
78. Baik SH, Cha MY, Hyun YM, Cho H, Hamza B, Kim DK, et al. Migration of neutrophils targeting amyloid plaques in Alzheimer's disease mouse model. Neurobiol Aging. (2014) 35:1286–92. doi: 10.1016/j.neurobiolaging.2014.01.003
79. Berton G, Laudanna C, Sorio C, Rossi F. Generation of signals activating neutrophil functions by leukocyte integrins: LFA-1 and gp150/95, but not CR3, are able to stimulate the respiratory burst of human neutrophils. J Cell Biol. (1992) 116:1007–17. doi: 10.1083/jcb.116.4.1007
80. Laudanna C, Constantin G, Baron P, Scarpini E, Scarlato G, Cabrini G, et al. Sulfatides trigger increase of cytosolic free calcium and enhanced expression of tumor necrosis factor-alpha and interleukin-8 mRNA in human neutrophils. Evidence for a role of L-selectin as a signaling molecule. J Biol Chem. (1994) 269:4021–6. doi: 10.2172/1201951
81. Waddell TK, Falkow L, Chan CK, Kishimoto TK, Downey GP. Potentiation of the oxidative burst of human neutrophils. A signaling role for L-selectin. J Biol Chem. (1994) 269:18485–91. doi: 10.2172/1201951
82. Montresor A, Toffali L, Constantin G, Lauda C. Chemokines and the signaling modules regulating integrin affinity. Front Immunol. (2012) 3:127. doi: 10.3389/fimmu.2012.00127
83. Fumagalli L, Campa CC, Gemma G, Lowell CA, Hirsch E, Berton G. Class I phosphoinositol 3-kinases and SRC kinases play a nonredundant role in regulation of adhesion-independent and -dependent neutrophil reactive oxygen species generation. J Immunol. (2013) 190:3648–60. doi: 10.4049/jimmunol.1201951
84. Bolton SJ, Anthony DC, Perry VH. Loss of the tight junction protein occludin and zona occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience. (1998) 86:1245–57. doi: 10.1016/S0306-4522(98)00058-X
85. Blamire AM, Anthony DC, Rajagopalan B, Sibson NR, Perry VH, Styles P. Interleukin-1beta-induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study. J Neurosci. (2000) 20:8153–60. doi: 10.1523/JNEUROSCI.20-21-08153.2000 86. Gautam N, Herwald H, Hedqvist P, Lindbom L. Monitoring of blood vessels and tissues by a population of neutrophils in vivo. Nat Immunol. (2007) 204:3037–47. doi: 10.1084/jem.20050011
87. Allen C, Thornpton P, Denes A, McColl BW, Pierrozynski A, Monesteri M, et al. Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol. (2012) 189:381–92. doi: 10.4049/jimmunol.1200409
88. Pietronigro EC, Della Bianca V, Zenaro E, Constantin G. Anti-alpha4beta1 integrin antibodies attenuated brain inflammatory changes in a mouse model of Alzheimer's disease. Curr Alzheimer Res. (2018) 15:1123–35. doi: 10.2174/1567205015661809111033
89. Geoffroy C, Della Bianca V, Zenaro E, Constantin G. NETosis in Alzheimer's disease. Front Immunol. (2017) 8:211. doi: 10.3389/fimmu.2017.00211
90. Manda-Handzlik A, Demkow U. The brain entangled: the contribution of microglia phenotypes. BMC Neurobiol. (2014) 38:321–9. doi: 10.1159/000360606
91. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol. (2002) 124:83–92. doi: 10.1016/S0165-5728(01)00496-9
92. Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, et al. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. (2019) 19:116. doi: 10.1186/s12883-019-1337-z
93. Mittal K, Eremenko E, Berner O, Elyahu Y, Strominger J, Apelblat P, et al. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain. (2010) 133(Pt 12):3699–723. doi: 10.1172/JCI41240
94. Dodiya HB, Kuntz T, Shaik SM, Baufeld C, Leibowitz J, Zhang X, et al. Monitoring of blood vessels and tissues by a population of neutrophils in vivo. J Exp Med. (2009) 200:1805–14. doi: 10.1084/jem.20050011
95. Booss J, Esiri MM, Tourtellotte WW, Mason DY. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci. (1983) 62:219–232. doi: 10.1016/0022-510X(83)90201-0
96. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science. (1983) 219:308–10. doi: 10.1126/science.6217550
97. Hauser SL, Blan AK, Gilles F, Kemp M, Kerr C, Weiner HL. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol. (1986) 19:578–87. doi: 10.1002/ana.410190610
98. Rogers J, Luber-Narod J, Styren SD, Cavin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. (1988) 9:339–49. doi: 10.1016/S0197-4580(88)80079-4
114. Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. (2019) 29:787–803. doi: 10.1038/s41422-019-0216-x

115. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Clonal expansions of CD8(+ ) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp. Med. (2000) 192:393–404. doi: 10.1084/jem.192.3.393

116. Salou M, Garcia A, Michel L, Gainche-Salmon A, Loussouarn D, Nicol B, et al. Expanded CD8 T-cell sharing between periphery and CNS in multiple sclerosis. Ann Clin Transl Neurol. (2015) 2:609–22. doi: 10.1002/acn3.199

117. Gate D, Saligrana N, Leventhal O, Yang AC, Unger MS, Middeldorp J, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature. (2020) 577:399–404. doi: 10.1038/s41586-019-1895-7

118. Unger MS, Li E, Scharnagl L, Poupardin R, Altendorfer B, Mrowetz H, et al. CD8(+ ) T-cells infiltrate Alzheimer’s disease brains and regulate neuronal- and synapse-related gene expression in APP-PS1 transgenic mice. Brain Behav Immun. (2020) 89:67–86. doi: 10.1016/j.bbi.2020.05.070

119. Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, et al. Increased CD8(+) cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. (2004) 172:5120–7. doi: 10.4049/jimmunol.172.8.5120

120. Crawford MP, Yan SX, Ortega SB, Mehta RS, Hewitt RE, Price DA, et al. High prevalence of autoreactive, neuroantigen-specific CD8(+) T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood. (2004) 103:4222–31. doi: 10.1182/blood-2003-11-4025

121. Lug G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, et al. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiology of Aging. (2015) 36:81–9. doi: 10.1016/j.neurobiolaging.2014.08.008

122. Battistini L, Piccio L, Rossi B, Bach S, Galgani S, Gasperini C, et al. CD8(+) T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. J Biomed Sci. (2003) 10:4775–82. doi: 10.1182/blood-2002-10-3309

123. Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, et al. Clonal expansions of CD8(+) T-cell sharing between periphery and CNS in multiple sclerosis. J Neuroimmunol. (2007) 188:117–27. doi: 10.1016/j.jneuroim.2007.05.011

124. Faridar A, Thome AD, Zhao W, Thonhoff JR, Beers DR, Pascual YH, et al. Single-cell profiling identifies myeloid cell subsets with monocytes define a pathogenic subset in the central nervous system during autoimmune neuroinflammation. Nat Immunol. (2020) 21:525–34. doi: 10.1038/s41590-020-0661-1

125. Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, et al. Regulatory T cells drive disease progression in Alzheimer-like pathology. Brain. (2016) 139(Pt 4):1237–51. doi: 10.1093/brain/awv408

126. Lee WJ, Ye M, Kang GH, Lee C, Lee G, Choi DB, et al. Neuroprotective effects of CD4(+)CD25(+)Foxp3(+) regulatory T cells in a 3xTg-AD Alzheimer's disease model. Oncotarget. (2016) 7:69347–57. doi: 10.18632/oncotarget.12469

127. Zhang R, Rivest S. Age-related changes in synaptic markers and monocyte subsets link the cognitive decline of APP(Swe)/PS1 mice. Front Cell Neurosci. (2012) 6:51. doi: 10.3389/fncel.2012.00051

128. Zhang R, Miller RG, Madison C, Jin X, Honrada R, Harris W, et al. Systemic immune system alterations in early stages of Alzheimer's disease. J Neuroimmunol. (2013) 256:38–42. doi: 10.1016/j.jneuroim.2013.01.002

129. Lee WJ, Liao YC, Wang YF, Lin IF, Wang SJ, Fuh JL. Plasma MCP-1 and cognitive decline in patients with Alzheimer's disease and mild cognitive impairment: a two-year follow-up study. Sci Rep. (2018) 8:1280. doi: 10.1038/s41598-018-19807-y

130. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. (2011) 11:762–74. doi: 10.1038/nri3070

131. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4(+)CD25(+) regulatory T cells in patients with multiple sclerosis. J Exp. Med. (2004) 199:971–9. doi: 10.1084/jem.20031579

132. Domínguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper type 1-like, Foxp3(+) regulatory T cells in human autoimmune disease. Nat Med. (2011) 17:673–5. doi: 10.1038/nm.2389

133. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol. (2007) 188:117–27. doi: 10.1016/j.jneuroim.2007.05.011

134. Akirav EM, Bergman CM, Hill M, Ruddle NH. Depletion of CD4(+)/CD25(+) T cells exacerbates experimental autoimmune encephalomyelitis induced by mouse, but not rat, antigens. J Neurosci. (2009) 87:3511–9. doi: 10.1523/jneurosci.021981

135. McIntyre LL, Greilach SA, Othy S, Sears-Kraxberger I, Wi B, Ayala-Angulo J, et al. Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant. Neurobiol Dis. (2020) 140:104868. doi: 10.1016/j.nbd.2020.104868

136. Li PL, Zavala A, Hingco E, Tran H, Cohen R, Lane TE, et al. Remyelination is correlated with regulatory T cell induction following human embryoid body-derived neural precursor cell transplantation in a viral model of multiple sclerosis. PLoS ONE. (2016) 11:e0157620. doi: 10.1371/journal.pone.0157620

137. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al. Characterization of naive, memory and effector T cells in progressive multiple sclerosis. J Neuroimmunol. (2017) 310:17–25. doi: 10.1016/j.jneuroim.2017.06.001

138. Serafini B, Rioscarelli B, Veroni C, Mazzola GA, Aloisi F. Epstein-Barr Virus-Specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J Virol. (1993) 67:9088–90. doi:10.1128/JVI.67.11.9088-90

139. Bjerg L, Bresol-Ravnborg A, Torring C, Dige A, Bundgaard R, Petersen T, et al. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients. J Neuroimmunol. (2012) 249:76–82. doi: 10.1016/j.jneuroim.2012.04.012

140. Kouchaki E, Salehi M, Reza Sharifi M, Nikoueinejad H, Akbari H. Numerical status of CD4(+)/CD25(+)Foxp3(+) and CD8(+)CD28(−) regulatory T cells in multiple sclerosis. Iran J Basic Med Sci. (2014) 17:250–5. doi:10.22038/ijbms.2014.2389

141. Ciccocioppo F, Lamuti P, Pederdomeco L, Simeone P, Bologna G, Ercolino E, et al. The characterization of regulatory T-cell profiles in Alzheimer’s disease and multiple sclerosis. Sci Rep. (2019) 9:8788. doi:10.1038/s41598-019-45433-3
190. Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. *Brain*. (2017) 140:184–200. doi: 10.1093/brain/aws270

191. Ferretti MT, Merlini M, Spani C, Gericke C, Schweizer N, Enzmann G, et al. T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer's disease-like cerebral amyloidosis. *Brain Behav Immun.* (2016) 54:211–25. doi: 10.1016/j.bbi.2016.02.009

192. Capece T, Walling BL, Lim K, Kim KD, Bae S, Chung HL, et al. A novel intracellular pool of LFA-1 is critical for asymmetric CD8(+) T cell activation and differentiation. *J Cell Biol.* (2017) 216:3817–29. doi: 10.1083/jcb.201609072

193. Serafini B, Rosicelli B, Magliozzi R, Stigliano E, Capello E, Mancardi GL, et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. *J Neuropathol Exp Neurol.* (2006) 65:124–41. doi: 10.1093/jnen/65.2.124

194. Merlini M, Kirabali T, Kulic L, Nitsch RM, Ferretti MT. Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study. *Neurodegener Dis.* (2018) 18:49–56. doi: 10.1159/000486200

195. Verma K, Ogonek J, Varanasi PR, Luther S, Bunting I, Thomay K, et al. Human CD8(+) CD57(+) TEMRA cells: Too young to be called “old.” *PLoS ONE.* (2012) 7:e177405. doi: 10.1371/journal.pone.0177405

196. Cebrian C, Loike JD, Sulzer D. Neuronal MHC-I expression and its implications in synaptic function, axonal regeneration and Parkin’s and other brain diseases. *Front Neuroanat.* (2014) 8:114. doi: 10.3389/fnana.2014.00114

197. Cerovic M, Forlioni G, Balducci C. Neuroinflammation and the gut microbiota; possible alternative therapeutic targets to counteract Alzheimer's disease? *Front Aging Neurosci.* (2019) 11:284. doi: 10.3389/fnagi.2019.00284

198. Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF. Impact of microbiota taxa and peripheral inflammation markers in cognitively impaired elderly. *Clin Exp Immunol.* (2018) 171:10719–24. doi: 10.1093/iceim/nby073

199. Laurent C, Dorothee G, Hunot S, Martin E, Monnet Y, Duchamp M, et al. Peripheral Immunity in Neurodegeneration. *Prog Neurobiol.* (2017) 141:1900–16. doi: 10.1016/j.pneu.2017.10.003

200. Schreiber HA, Loschko J, Karssemeijer RA, Escolano A, Meredith MM, Mucida D, et al. Intestinal monocytes and macrophages are required for T cell polarization in response to *Citrobacter rodentium*. *J Exp Med.* (2016) 210:2025–39. doi: 10.1084/jem.20130903

201. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci USA.* (2011) 108(Suppl. 1):4615–22. doi: 10.1073/pnas.1006082107

202. Cekanaviciute E, Yoo BB, Kunia TF, Debuelis JW, Singh S, Nelson CA, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. *Proc Natl Acad Sci USA.* (2017) 114:10713–8. doi: 10.1073/pnas.1711233114

203. Wang Y, Telesford KM, Ochoa-Reparaz J, Haque-Begum S, Christy M, Kasper EL, et al. An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling. *Nat Commun.* (2014) 5:4432. doi: 10.1038/ncomms5432

204. Kadowaki A, Saga R, Lin Y, Sato W, Yamamura T. Gut microbiota-dependent CCR9(CD4)+ T cells are altered in secondary progressive multiple sclerosis. *Brain.* (2019) 142:916–31. doi: 10.1093/brain/awz012

205. Gagliano SA, Pouget JG, Hardy J, Knight J, Barnes MR, Ryten M, et al. Genomics implicates adaptive and innate immune in Alzheimer's and Parkinson's diseases. *Ann Clin Transl Neurol.* (2016) 3:924–33. doi: 10.1002/acn3.369

206. Hao S, Wang R, Zhang Y, Zhan H. Prediction of Alzheimer's disease-associated genes by integration of gwas summary data and expression data. *Front Genet.* (2016) 9:653. doi: 10.3389/fgene.2016.00653

207. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science.* (2013) 345:eaaw7188. doi: 10.1126/science.aaaw7188

208. Sotgiu S, Murrighile MR, Constantin G. Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. *Case report BMC Neurol.* (2010) 10:84. doi: 10.1186/1471-2377-10-84

209. Angjari S, Constantin G. Selectins and their ligands as potential immunotherapeutic targets in neurological diseases. *Immunotherapy.* (2013) 5:1207–20. doi: 10.2217/imt.13.122

210. Fabene PF, Laudanna C, Constantin G. Leukocyte trafficking mechanisms in epilepsy. *Mol Immunol.* (2013) 55:100–4. doi: 10.1016/j.molimm.2012.12.009

211. Montague A, Zhao Z, Zlokovic BV. Alzheimer's disease: a matter of blood-brain barrier dysfunction? *J Exp Med.* (2014) 211:2031–69. doi: 10.1084/jem.20131008

212. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nat Rev Neurol.* (2014) 10:843–50. doi: 10.1038/nrneurol.2013.188

213. Van Skike CE, Jahrling JB, Olson AB, Sayre NL, Hussong SA, Ungvari Z, et al. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment. *Ann Physiol Heart Circ Physiol.* (2018) 314:H693–703. doi: 10.1152/ajpheart.00570.2017

214. Zeitelhofer M, Adzemovic MZ, Moesinger C, Stefanitsch C, Strell C, Muhl L, et al. Blocking PDGF-CC signaling ameliorates multiple sclerosis-like neuroinflammation by inhibiting disruption of the blood-brain barrier. *Sci Rep.* (2020) 10:22283. doi: 10.1038/s41598-020-79598-z

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Rossi, Santos-Lima, Ternabua, Zenoaro and Constantin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.